22 June 2012: The new Board of Directors had their first board meeting succeeding the annual meeting of shareholders. The board has decided to start a strategy evaluation process in order to determine the strategic direction for the company. This process is expected to be finalised in September/October 2012. Further more the Board of Directors has decided to hire PhD Dagfinn Øgreid as Medical Director of NORDA ASA in order to investigate the possibility for a further development of the Genfect colorectal cancer test in collaboration with international partners.

In light of increased risk in the cost and revenue estimates relating to open balances related to divested sample preparation business, the board has decide to adjust the expected net proceeds from the sale to a range of MNOK 32-22.

For further information, please contact:
CEO Hans Hekland - Phone: +47 906 26 870

 Read the notice in Norwegian here.